A Danish cohort study revealed that newer glucose-lowering drugs, specifically sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, were linked to reduced risks of cardiovascular events and heart failure hospitalization in individuals aged 70 and older with type 2 diabetes. The study included 35,679 participants and demonstrated the cardiovascular benefits of these medications, emphasizing their potential for implementation in guidelines for cardiovascular risk reduction in older adults with type 2 diabetes.

Source: eClinicalMedicine